Welcome international healthcare professionals

Welcome, this website is intended for Non-US international healthcare professionals with an interest in the treatment of lymphoma. By clicking the link below you are declaring and confirming that you are a healthcare professional.

You are here

Christian Gisselbrecht, MD

Christian Gisselbrecht, MD, is a Professor of Haematology in the Haemato-Oncology Department of Hôpital Saint-Louis, at Diderot University Paris 7, in Paris, France. He received his MD from the University of Paris. He completed a residency in haematology and served as Chief Resident, and earned a Molecular Biology certificate from the Faculty of Sciences, Paris 7, and an Oncology certificate from Hôpital Saint-Louis. He has also been a Visiting Associate at the National Institutes of Health, Bethesda, USA.

Professor Gisselbrecht is co-founder of the Groupe d’Etude des Lymphomes de l’Adulte (GELA), a French-Belgian cooperative group which has organized numerous randomized trials in lymphoma since 1984. He was President of the group until 2002. GELA has recently extended its activities and changed its name to Lymphoma Study Association (LYSA). He and his research group are currently undertaking prospective trials to investigate the combination of dose-intensive chemotherapy and monoclonal antibodies in lymphoma.

He has been Principal Investigator of several major phase 2 and phase 3 clinical trials that investigated the place of autologous stem cell transplantation in the treatment of lymphoma. Currently, he is Chair of the international CORAL study on relapsed diffuse large B-cell lymphoma. His research interests include clinicopathological correlative studies in lymphoma, the pharmacology of novel antineoplastic agents, and stem cell transplantation with a focus on relapsed or poor-prognosis lymphoma and T-cell lymphoma.

Professor Gisselbrecht is an active member of several European and American scientific societies and has served as an expert with the French Agency for the Safety of Healthcare Products (AFSSAPS), as well as several cancer research agencies. He has published over 300 peer-reviewed papers and several book chapters and is on the editorial board of a number of highly respected journals.